Due to the potential of BIONIME’s excellent technology, development team and the market for blood sugar monitoring, the CBVM decided to invest in BIONIME on January 31 2005. Apart from the financial investment, the CBVM’s immense network of bioscience contacts overseas is also available to assist in the future growth of BIONIME.